COMMUNIQUÉS West-GlobeNewswire

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
25/03/2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology [...]
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
26/03/2026
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of [...]
XORTX Announces Share Consolidation
25/03/2026
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
25/03/2026
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales Expanded [...]
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
25/03/2026
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
25/03/2026
Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued [...]
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
25/03/2026
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in [...]
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
25/03/2026
- FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
25/03/2026
Application to upgrade market tier approved WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive [...]
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the [...]
American Nurses Enterprise Launches 2026–2030 Strategic Plan, Charting a Bold New Direction for the Future of Nursing
25/03/2026
Marking ANA's 130th Anniversary, ANE Sets a New Strategic Course to Advance the Nursing Profession SILVER SPRING, MD, March 25, 2026 (GLOBE NEWSWIRE) -- The American Nurses Enterprise (ANE), the unifying force behind [...]
Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
25/03/2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 [...]
BeyondSpring Files 2025 Annual Report on Form 10-K
25/03/2026
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and [...]
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
25/03/2026
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
25/03/2026
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the [...]

Pages